161 filings
Page 6 of 9
8-K
php rm38x5u6n
18 Sep 17
Departure of Directors or Certain Officers
12:00am
8-K
5qvpq 4vv6aj00o
1 Sep 17
Departure of Directors or Certain Officers
12:00am
8-K
wit8 guhh
14 Jun 17
Departure of Directors or Certain Officers
12:00am
8-K
eidya6 86j01pxcaqj91
12 May 17
Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
12:00am
8-K
ugwxst vx
23 Mar 17
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
12:00am
8-K
7011j93ky059yapbvuen
5 Jan 17
Entry into a Material Definitive Agreement
12:00am
8-K
d9xcz
17 Nov 16
Regulation FD Disclosure
12:00am
8-K
1kt6rn5xv67r 6zon
1 Sep 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
171devhefj ds55de6
19 Aug 16
Other Events
12:00am
8-K
6bdvw3l te0
17 Aug 16
Other Events
12:00am
8-K
ubl6irmea66m561jqh
28 Jul 16
Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
12:00am
8-K
k8pfno0m wrue
23 Jun 16
Entry into a Material Definitive Agreement
12:00am
8-K/A
6hsaokr4lb1ykjj3vufm
17 Jun 16
Financial Statements and Exhibits
12:00am
8-K
4xgga1zu1avkjn95i0k
16 Jun 16
Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
12:00am
8-K
4415wtg7li93k
18 May 16
Eiger BioPharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
12:00am
8-K/A
66ii 3d6bk7hc88
13 May 16
Financial Statements and Exhibits
12:00am
8-K
nkpke f7f3vawt
28 Apr 16
Changes in Registrant's Certifying Accountant
12:00am
8-K
rmv2s5g
20 Apr 16
Entry into a Material Definitive Agreement
12:00am
8-K
55dbmrnpaw562vb22
1 Apr 16
Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency
12:00am
8-K
42e7f7n4ionbkk7
23 Mar 16
Eiger BioPharmaceuticals Closes Merger With Celladon
12:00am